Transparency in clinical trials is continually changing, and to stay on top of the news, TrialAssure brings a weekly round-up of some of the key stories surrounding disclosures in clinical trials. This week’s stories are as follows:
Only half of post-marketing commitments get published in peer-reviewed journals, study shows – PharmaLive
A study recently published in BMC Medicine showed that only half of all post-marketing commitments agreed to between the FDA and drug manufacturers are published in peer-reviewed journals. This study shows the ongoing concerns over transparency in the drug development space.
Alex Keown has the full story here
Fantastic news: UK universities get serious about clinical trial transparency – TranspariMED
Over the past months, most UK universities are working to improve their clinical trial reporting. Some have adopted plans for the future, feeling pressure from the government, researchers, and the public.
Read the full article by Till Bruckner via TranspariMED
FDA improves transparency and predictability for generic drug applicants – PharmTech
The FDA recently announced that it is improving communications with generic-drug applicants about the potential for their products to be able to be approved and marketed. The federal agency is achieving this by adding data points to its Paragraph IV Patent Certifications List.
Learn more about this story via Pharmatech.com
